A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

A major trial testing multiple sclerosis drug evobrutinib failed in December last year. Merck, which previously predicted ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Overall, this study thus showed that the FasL inhibitor was safe and well tolerated by the patients and achieved very promising results for the efficacy of this drug in patients with severe COVID-19.

And of course, do keep in touch. We get lonely easily. … U.S. Food and Drug Administration Commissioner Robert Califf is ...